# US 2025/0375470 A1 · Hydroxypropyl beta-cyclodextrin compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375470 A1
- Document ID: US20250375470A1
- Status: Published application
- Kind: A1
- Application number: 19/312,906
- Filed: 2025-08-28
- Published: 2025-12-11
- Earliest claimed: 2015-06-10
- Assignees: Mandos LLC
- Applicants: Mandos LLC
- Inventors: Bernardus Nicolaas Machielse; Allan Darling
- Web page: https://patentgrep.com/patent/US20250375470A1

## CPC

- A61K 31/724: Cyclodextrins
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

## Claims

### Claim 1

A method of increasing ATG5, VPS15, ATG18, or ATG101 expression levels in a subject in need thereof, comprising administering to the subject a composition comprising a pharmaceutically effective amount of a mixture of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, wherein the composition comprises less than 10 International Units (IU) of endotoxins per gram.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition comprises less than 8 IU of endotoxins per gram.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition comprises less than 6 IU of endotoxins per gram.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition comprises less than 5 IU of endotoxins per gram.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition comprises less than 4 IU of endotoxins per gram.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition comprises less than 3 IU of endotoxins per gram.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition comprises less than 1 ppm propylene oxide.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition comprises less than 0.8 ppm propylene oxide.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition comprises less than 0.6 ppm propylene oxide.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition comprises less than 0.5 ppm propylene oxide.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition is suitable for intrathecal administration.

### Claim 12 (depends on 1)

The method of claim 1, wherein the mixture of beta-cyclodextrin molecules comprises less than 1% unsubstituted beta-cyclodextrin (“DS-0”).

### Claim 13 (depends on 1)

The method of claim 1, wherein the mixture of beta-cyclodextrin molecules comprises 10% to 30% molecules having three hydroxypropyl substitutions (“DS-3”).

### Claim 14 (depends on 1)

The method of claim 1, wherein the mixture of beta-cyclodextrin molecules comprises at least 75% molecules having three, four, five, and six hydroxypropyl substitutions, collectively (“DS-3”, “DS-4”, “DS-5”, and “DS-6”).

### Claim 15 (depends on 1)

The method of claim 1, wherein the mixture of beta-cyclodextrin molecules comprises less than 1% molecules having nine and ten hydroxypropyl substitutions, collectively (“DS-9” and “DS-10”).

### Claim 16 (depends on 1)

The method of claim 1, wherein the mixture of beta-cyclodextrin molecules comprises less than 0.1% molecules having nine and ten hydroxypropyl substitutions, collectively (“DS-9” and “DS-10”).

### Claim 17 (depends on 1)

The method of claim 1, wherein the composition comprises less than 0.9% propylene glycol.

### Claim 18 (depends on 1)

The method of claim 1, wherein the composition comprises less than 0.8% propylene glycol.

### Claim 19 (depends on 1)

The method of claim 1, wherein the composition comprises less than 0.7% propylene glycol.

### Claim 20 (depends on 1)

The method of claim 1, wherein the composition comprises less than 0.6% propylene glycol.

### Claim 21 (depends on 1)

The method of claim 1, wherein the composition further comprises sodium chloride.

### Claim 22 (depends on 1)

The method of claim 1, wherein the composition is suitable for lumbar injection.

### Claim 23

A method of increasing ATG5 or VPS15 expression levels in a subject in need thereof, comprising administering to the subject a composition comprising a pharmaceutically effective amount of a mixture of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, wherein the composition comprises less than 10 International Units (IU) of endotoxins per gram.

### Claim 24 (depends on 23)

The method of claim 23, wherein the composition comprises less than 8 IU of endotoxins per gram.

### Claim 25 (depends on 23)

The method of claim 23, wherein the composition comprises less than 5 IU of endotoxins per gram.

### Claim 26 (depends on 23)

The method of claim 23, wherein the composition comprises less than 1 ppm propylene oxide.

### Claim 27

A method of increasing ATG18 or ATG101 expression levels in a subject in need thereof, comprising administering to the subject a composition comprising a pharmaceutically effective amount of a mixture of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, wherein the composition comprises less than 10 International Units (IU) of endotoxins per gram.

### Claim 28 (depends on 27)

The method of claim 27, wherein the composition comprises less than 8 IU of endotoxins per gram.

### Claim 29 (depends on 27)

The method of claim 27, wherein the composition comprises less than 5 IU of endotoxins per gram.

### Claim 30 (depends on 27)

The method of claim 27, wherein the composition comprises less than 1 ppm propylene oxide.
